Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics


Arbutus Biopharma Corporation (ABUS): $4.08

-0.07 (-1.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

ABUS POWR Grades


  • ABUS scores best on the Growth dimension, with a Growth rank ahead of 77.38% of US stocks.
  • ABUS's strongest trending metric is Quality; it's been moving down over the last 51 weeks.
  • ABUS ranks lowest in Momentum; there it ranks in the 9th percentile.

ABUS Stock Summary

  • Of note is the ratio of Arbutus Biopharma Corp's sales and general administrative expense to its total operating expenses; just 9.92% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Arbutus Biopharma Corp is higher than it is for about only 8.38% of US stocks.
  • With a price/sales ratio of 49.28, Arbutus Biopharma Corp has a higher such ratio than 95.15% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arbutus Biopharma Corp are WVE, IMGN, PLRX, TTNP, and MGNX.
  • Visit ABUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arbutusbio.com.

ABUS Valuation Summary

  • In comparison to the median Healthcare stock, ABUS's EV/EBIT ratio is 115.7% lower, now standing at -4.6.
  • Over the past 142 months, ABUS's price/earnings ratio has gone up 1.4.
  • ABUS's price/sales ratio has moved up 37.4 over the prior 142 months.

Below are key valuation metrics over time for ABUS.

Stock Date P/S P/B P/E EV/EBIT
ABUS 2021-08-31 40.7 3.4 -4.0 -4.6
ABUS 2021-08-30 40.1 3.3 -4.0 -4.5
ABUS 2021-08-27 39.5 3.3 -3.9 -4.4
ABUS 2021-08-26 38.6 3.2 -3.8 -4.3
ABUS 2021-08-25 38.7 3.2 -3.8 -4.3
ABUS 2021-08-24 38.6 3.2 -3.8 -4.3

ABUS Growth Metrics

  • The 3 year price growth rate now stands at -43.32%.
  • Its 5 year net income to common stockholders growth rate is now at -151.1%.
  • Its year over year cash and equivalents growth rate is now at 200.65%.
ABUS's revenue has moved down $8,186,000 over the prior 70 months.

The table below shows ABUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 8.351 -59.077 -84.193
2021-03-31 7.536 -53.869 -78.622
2020-12-31 6.914 -51.441 -75.868
2020-09-30 6.146 -49.779 -83.237
2020-06-30 7.684 -61.075 -146.75
2020-03-31 6.823 -69.879 -155.745

ABUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABUS has a Quality Grade of D, ranking ahead of 24.73% of graded US stocks.
  • ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
  • PLXP, HSTO, and AGTC are the stocks whose asset turnover ratios are most correlated with ABUS.

The table below shows ABUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 1 -1.012
2021-03-31 0.059 1 -1.139
2020-12-31 0.059 1 -1.030
2020-09-30 0.056 1 -1.204
2020-06-30 0.073 1 -2.668
2020-03-31 0.053 1 -3.000

ABUS Price Target

For more insight on analysts targets of ABUS, see our ABUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 1.7 (Moderate Buy)

ABUS Stock Price Chart Interactive Chart >

Price chart for ABUS

ABUS Price/Volume Stats

Current price $4.08 52-week high $5.87
Prev. close $4.15 52-week low $2.43
Day low $4.02 Volume 2,365,500
Day high $4.18 Avg. volume 2,184,281
50-day MA $3.77 Dividend yield N/A
200-day MA $3.46 Market Cap 404.58M

Arbutus Biopharma Corporation (ABUS) Company Bio


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.


ABUS Latest News Stream


Event/Time News Detail
Loading, please wait...

ABUS Latest Social Stream


Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Arbutus Biopharma (NASDAQ:ABUS) shareholders have earned a 7.3% CAGR over the last five years

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...

Yahoo | October 13, 2021

Why Moderna Stock Is Rebounding Today

Shares of Moderna (NASDAQ: MRNA) were rebounding somewhat on Thursday after several days of declines. Moderna actually had more bad news today. Finland joined Denmark and Sweden in pausing the use of the company's COVID-19 vaccine for some individuals due to concerns about a rare heart inflammation issue.

Yahoo | October 7, 2021

Thinking about buying stock in Tata Motors, New Fortress Energy, Arbutus Biopharma, US Well Services, or Progenity?

InvestorsObserver issues critical PriceWatch Alerts for TTM, NFE, ABUS, USWS, and PROG.

Yahoo | October 7, 2021

Arbutus to Participate in October Investor Conferences

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences: Chardan’s 5th Annual Genetic Medicines Conference – Virtual (Oc

Yahoo | September 28, 2021

Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Yahoo | September 27, 2021

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo -6.21%
3-mo 50.55%
6-mo 36.45%
1-year 32.90%
3-year -8.11%
5-year 36.91%
YTD 14.93%
2020 27.70%
2019 -27.42%
2018 -24.16%
2017 106.12%
2016 -44.94%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8485 seconds.